Premium
Factors for graft‐ versus ‐host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose
Author(s) -
Fozza C.,
Szydlo R.M.,
AbdelRehim M.M.,
Nadal E.,
Goldman J.M.,
Apperley J.F.,
Dazzi F.
Publication year - 2007
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2007.06501.x
Subject(s) - medicine , regimen , lymphocyte , donor lymphocyte infusion , graft versus host disease , incidence (geometry) , multivariate analysis , immunology , disease , hematopoietic cell , gastroenterology , haematopoiesis , stem cell , physics , biology , optics , genetics
Summary We investigated the risk factors for graft‐ versus ‐host disease (GVHD) in 82 patients treated with donor lymphocyte infusions (DLI) using an escalating dose regimen for chronic myeloid leukaemia in relapse following conventional allografting. Two factors emerged as predictors of both acute and chronic GVHD: the infusion of male recipients with lymphocytes from a female donor and the interval between transplant and last DLI, but only the first remained significant at multivariate analysis. Surprisingly, lymphocyte dose did not influence the incidence of GVHD. Our results suggest that DLI can be given in large cell doses without increasing the risk of GVHD.